Crinetics Pharmaceuticals, Inc. (CRNX)
CRNX · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2015
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts in thousands. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
| Report filed | Feb 26, 2026 | Feb 27, 2025 | Feb 28, 2024 | Feb 28, 2023 | Mar 30, 2022 | Mar 30, 2021 | Mar 9, 2020 | Mar 13, 2019 | · | · |
| Revenue | 7,696 | 1,039 | 4,013 | 0 | 0 | 71 | 1,193 | 2,428 | 2,045 | 589 |
| Cost of revenue | 1,076 | 0 | 0 | · | · | · | · | · | · | · |
| Research and development | 332,058 | 240,156 | 168,527 | 130,225 | 84,255 | 56,998 | 41,506 | 24,479 | 9,233 | 5,100 |
| Selling, general and administrative | 191,331 | 99,737 | 58,094 | · | · | · | · | · | · | · |
| General and administrative | · | 99,737 | 58,094 | 42,394 | 24,525 | 18,026 | 13,519 | 6,659 | 1,939 | 1,533 |
| Total operating expenses | · | 339,893 | 226,621 | 172,619 | 108,780 | 75,024 | 55,025 | 31,138 | 11,172 | 6,633 |
| Total costs and expenses | 524,465 | 339,893 | 226,621 | · | · | · | · | · | · | · |
| Operating income | -516,769 | -338,854 | -222,608 | -167,882 | -107,702 | -74,953 | -53,832 | -28,710 | -9,127 | -6,044 |
| Interest expense | · | · | · | · | · | · | · | · | 8 | 11 |
| Interest and investment income | 51,989 | 41,435 | 13,436 | 4,317 | 157 | 991 | 3,460 | 1,748 | 26 | 37 |
| Share of profit of equity-method investments | 0 | -470 | -5,198 | · | · | · | · | · | · | · |
| Other income (expense), net | -357 | -519 | -159 | · | · | · | · | · | · | · |
| Total non-operating income (expense) | 51,632 | 40,916 | 13,277 | 4,974 | 61 | 1,141 | 3,410 | 1,595 | -30 | 25 |
| Income before income taxes | -465,137 | -297,938 | -209,331 | -163,918 | -107,641 | -73,812 | -50,422 | -27,115 | -9,157 | -6,019 |
| Income tax expense | 180 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -465,317 | -298,408 | -214,529 | -163,918 | -107,641 | -73,812 | -50,422 | -27,115 | -9,157 | -6,019 |
| Earnings per share, basic | -4.95 | -3.69 | -3.69 | -3.15 | -2.80 | -2.42 | · | · | · | · |
| Earnings per share, diluted | -4.95 | -3.69 | -3.69 | -3.15 | -2.80 | -2.42 | · | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -2.80 | -2.42 | -2.09 | -2.23 | -6.68 | -5.96 |
| Weighted average shares, basic | 94,057 | 80,783 | 58,071 | 51,982 | 38,436 | 30,448 | · | · | · | · |
| Weighted average shares, diluted | 94,057 | 80,783 | 58,071 | 51,982 | 38,436 | 30,448 | · | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | 38,436 | 30,448 | 24,175 | 12,142 | 1,371 | 1,011 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:Revenues
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTaxCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfRevenueResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesTotal costs and expenses every operating cost, the cost of revenue included
us-gaap:CostsAndExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestShare of profit of equity-method investments its share of companies it partly owns
us-gaap:IncomeLossFromEquityMethodInvestmentsOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted